Myriad Genetics (MYGN) CFO Reports 2,559 Shares Withheld to Cover Taxes
Rhea-AI Filing Summary
Benjamin R. Wheeler, Chief Financial Officer of Myriad Genetics (MYGN), reported a Form 4 showing shares withheld to cover taxes on vested restricted stock units. On 09/21/2025 the filing records 2,559 shares disposed (withheld) at an indicated price of $7.77 per share. After this withholding, Mr. Wheeler beneficially owns 92,651 shares. The filing explains the shares were withheld to satisfy tax withholding obligations and that the withheld amount was determined using Myriad's closing price on September 19, 2025.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine tax withholding on vested RSUs by the CFO; immaterial to company valuation but updates insider ownership.
The transaction is a standard administrative disposition where 2,559 shares were withheld to satisfy tax obligations tied to vested restricted stock units. This is not a market sale or signal of liquidity needs; it reduces the reporting person's direct share count to 92,651. For investors, the change is informational about insider holdings but not materially impactful to Myriad's capital structure or operations.
TL;DR: Administrative withholding following RSU vesting; consistent with common executive compensation practices.
The disclosure follows expected governance practices by reporting a tax-withholding disposition and specifying the method (withheld shares) and basis (closing price on September 19, 2025). The Form 4 provides transparency on insider ownership levels. There are no indications of atypical compensation arrangements or extraordinary insider dispositions in this filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 2,559 | $7.77 | $20K |
Footnotes (1)
- [object Object]
FAQ
What did Benjamin R. Wheeler report on the Form 4 for MYGN?
What is Benjamin R. Wheeler's role at Myriad listed in the Form 4?
Does this Form 4 indicate a market sale by the insider?